Filtered Image?height=270

News & Publications

News & insights

Penningtons Manches Cooper acts for SkinBioTherapeutics plc on placing and REX retail offer on AIM
Posted: 05/01/2023
The corporate team at Penningtons Manches Cooper has advised SkinBioTherapeutics plc (AIM: SBTX) on a £2.5 million placing, and a separate retail offer to existing shareholders through the REX platform, raising an additional £117,378. This is the second fundraising on AIM that Penningtons Manches Cooper has advised SkinBioTherapeutics on......>>
The Moderna v Pfizer-Biontech COVID-19 vaccine dispute: a brief explanation
Posted: 30/11/2022
Moderna’s patent infringement claim against Pfizer and BioNTech about its COVID-19 vaccine technology has been widely reported. After filing lawsuits in August 2022 in the US and Germany, Moderna has now launched related proceedings in the UK Patents Court. In response, Pfizer and BioNTech have issued separate UK claims......>>
Same old, same old but different: the proposed UK framework for medical device regulations
Posted: 21/11/2022
The Medicines and Healthcare products Regulatory Agency (MHRA) published its consultation response in June 2022. To the relief of the majority of stakeholders in this area, this will result in new regulations for the United Kingdom that broadly align with the EU Medical Devices Regulations and the In Vitro Diagnostic Device Regulations......>>
Penningtons Manches Cooper advises Seloxium on its spin-out from Oxford University
Posted: 07/11/2022
The corporate team at Penningtons Manches Cooper has advised Seloxium on the completion of its spin-out from Oxford University and initial seed funding led by Oxford Science Enterprises in cooperation with Oxford University Innovation, the University’s technology transfer office......>>
Patents to biological medicines in combination: is two really better than one?
Posted: 23/09/2022
New medicines are usually protected by a patent covering the active molecule. These basic or “primary” patents usually provide robust protection for the relevant product, provided that the compound is genuinely new and inventive......>>
The UK moves into the fast lane for biosimilar regulatory approvals
Posted: 29/07/2022
Biological medicines (‘biologics’) contain active substances from a biological source such as living cells, tissues, or organisms such as bacteria or yeast. Most contain active molecules which are proteins which may vary in size and structural complexity, from relatively simple proteins like insulin to relatively large and complex monoclonal antibodies......>>
Penningtons Manches Cooper advises Titian Software on majority investment from Battery Ventures
Posted: 12/07/2022
The corporate team at Penningtons Manches Cooper has advised shareholders of Titian Software, a leading sample management software solution provider to the life sciences sector, on the significant, majority investment from Battery Ventures, a US technology-focused investment firm. Titian will use the new funds to support organic growth as well as potential future acquisitions......>>
The In Vitro Diagnostic Medical Devices Regulation is here — a closer look at what you need to know
Posted: 06/07/2022
As with Regulation (EU) 2017/745, the Medical Devices Regulation (MDR), which simultaneously celebrates its one-year anniversary since its application from 26 May 2021, the IVDR intends to provide comprehensive and harmonised regulation of the supply of in-vitro diagnostic medical devices (IVD) such as blood glucose monitors......>>
Penningtons Manches Cooper advises US company Echo Healthcare on its cross-border acquisition of Immersive Interactive
Posted: 17/06/2022
The corporate team at Penningtons Manches Cooper has advised Echo Healthcare Inc, a US medtech company, on its strategic cross-border acquisition of Immersive Interactive......>>
Comparing the EU clinical trials regulation and the MHRA consultation on clinical trials
Posted: 23/05/2022
Life sciences analysis: Rachel Bradley, partner, and Shaan Mehra and Clemency Pleming, trainee solicitors, explain the key provisions of the new EU Clinical Trials Regulation and considers how these compare with the main proposals in the MHRA’s consultation on the UK clinical trials regime......>>

1
2
3
4
5
6
7
8
9

Filter news & insights

Filter by keyword: Filter by expertise:

In this section

Media enquiries

Contact our press team on:

+44 (0)20 7457 3258
+44 (0)7887 888105 (out of hours)

Useful links

Value

Contact an office

London (Head office)
+44 (0)20 7457 3000
London (Minories)
+44 (0)20 7481 8851
Basingstoke
+44 (0)1256 407100
Birmingham
+44 (0)121 312 2560
Cambridge
+44 (0)1223 465465
Guildford
+44 (0)1483 791800
Oxford
+44 (0)1865 722106
Reading
+44 (0)118 982 2640

Madrid
+34 91 781 6670
Paris
+33 1 44 34 24 80
Piraeus
+30 210 361 4840
Singapore
+65 6438 4497

Sectors

Services for Business

Services for Individuals

Copyright

© 2023 Penningtons Manches Cooper LLP.
All rights reserved.
Website design by Frontmedia / Dynamic Pear

Penningtons Manches Cooper LLP

Penningtons Manches Cooper LLP is a limited liability partnership registered in England and Wales with registered number OC311575 and is authorised and regulated by the Solicitors Regulation Authority.